
    
      Patients with recent-onset CRVO (lasting for less than 1 month)are randomly assigned to one
      of 3 groups: hemodilution using erythrocytapheresis alone, 3 monthly injection of ranibizumab
      alone, or both.

      Patients are followed monthly during the 6-month study.
    
  